Creemers, A.
ter Veer, E.
de Waal, L.
Lodder, P.
Hooijer, G. K. J.
van Grieken, N. C. T.
Bijlsma, M. F.
Meijer, S. L.
van Oijen, M. G. H.
van Laarhoven, H. W. M.
Article History
Received: 5 January 2017
Accepted: 26 April 2017
First Online: 9 June 2017
Competing Interests
: Dr. Martijn G. H. van Oijen has received unrestricted research grants from Bayer, Lilly, Merck Serono, and Roche. Prof. dr. Hanneke W. M. van Laarhoven has served as a consultant for Celgene, Lilly, and Nordic, and has received unrestricted research funding from Bayer, Celgene, Lilly, Merck Serono, MSD, Nordic, and Roche. None of these parties was involved in drafting this review.